QuidelOrtho earnings beat by $0.11, revenue fell short of estimates
QuidelOrtho (QDEL) reported Q3 EPS of $0.31, beating estimates by $0.11, but revenue of $618.9M missed expectations. FY 2026 guidance: EPS $0.65-$0.90 (vs. consensus $0.77) and revenue $2.52B-$2.60B (vs. consensus $2.54B). Stock up 14.69% in 3 months, down 48.06% in 1 year.
How this was made
The 30-second read
Why it matters
Earnings beat on EPS but revenue miss may cause short‑term volatility; guidance suggests upside if lower bound is met.
Market read
First‑report earnings data for QDEL; relevant for traders monitoring healthcare diagnostics earnings season.
What to watch
Guidance range still above consensus on the low end, offering upside potential if the company meets the lower bound.
Background
QuidelOrtho is a diagnostics company listed on NASDAQ. The article provides its latest quarterly results and FY guidance.
Ticker impact
QDEL reported Q3 EPS $0.31 beating estimates by $0.11 and revenue $618.9M missing consensus, plus FY2026 guidance range.
likely modest downside pressure as revenue shortfall offsets EPS beat
Investors often prioritize top‑line growth; the miss of $9.2M versus consensus may trigger sell‑offs despite the EPS beat.
Market effects
Healthcare diagnostics sector may see mixed reaction as peers watch QDEL's revenue shortfall.
U.S. market may see slight pullback in related biotech stocks.
Limited global impact; primarily U.S. investors.
Counterpoint
The EPS beat could signal underlying strength; price may rally on momentum despite revenue miss.
Key entities
- companyQuidelOrtho
NASDAQ‑listed diagnostics firm reporting Q3 results.



